KRAS

Targeting SMPD1-Driven Sphingolipid Metabolism to Disrupt KRAS Signaling in Pancreatic Ductal Adenocarcinoma

This study reveals that dysregulated sphingolipid metabolism via SMPD1 supports KRAS-driven pancreatic cancer progression, identifying SMPD1 as a promising therapeutic target in pancreatic ductal adenocarcinoma.